Mirum Pharmaceuticals Inc (MIRM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mirum Pharmaceuticals Inc (MIRM) has a cash flow conversion efficiency ratio of -0.943x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-228.76 Million) by net assets ($242.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Mirum Pharmaceuticals Inc to measure how much of total assets are equity-financed.
Mirum Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Mirum Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check MIRM cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Mirum Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mirum Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lithia Motors Inc
NYSE:LAD
|
-0.017x |
|
Ringkjoebing Landbobank A/S
CO:RILBA
|
0.002x |
|
Broadex Technologies Co Ltd
SHE:300548
|
0.067x |
|
PSP Swiss Property AG
SW:PSPN
|
0.007x |
|
Enpro Industries
NYSE:NPO
|
0.025x |
|
Cpi Property Group SA
XETRA:O5G
|
0.029x |
|
Middleby Corp
NASDAQ:MIDD
|
0.069x |
|
AutoNation Inc
NYSE:AN
|
0.010x |
Annual Cash Flow Conversion Efficiency for Mirum Pharmaceuticals Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Mirum Pharmaceuticals Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Mirum Pharmaceuticals Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $314.69 Million | $55.83 Million | 0.177x | +287.69% |
| 2024-12-31 | $225.64 Million | $10.32 Million | 0.046x | +116.04% |
| 2023-12-31 | $248.67 Million | $-70.94 Million | -0.285x | +66.27% |
| 2022-12-31 | $142.04 Million | $-120.14 Million | -0.846x | +23.41% |
| 2021-12-31 | $120.21 Million | $-132.76 Million | -1.104x | -113.37% |
| 2020-12-31 | $172.09 Million | $-89.08 Million | -0.518x | -71.40% |
| 2019-12-31 | $130.35 Million | $-39.36 Million | -0.302x | -935.73% |
| 2018-12-31 | $-10.32 Million | $-373.00K | 0.036x | -- |
About Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille … Read more